Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update
So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research Mind Cure also continues to strengthen its proprietary digital therapeutics technology (“DTx”), iSTRYM All of Mind Cure’s decisions thus far are designed to help the company achieve overall growth and fulfill its vision of easing suffering, increasing productivity, and enhancing mental health Mind Cure…